Snapshot from Sep 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Business R&D Day

Immunic Hosts Relapsing MS R&D Day

Analysis based on 9 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026

Sentiment
10
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcement is a routine corporate communication that may generate modest interest among investors tracking Immunic's clinical progress. The upcoming R&D day could provide insights into the potential of vidofludimus calcium, but no immediate market impact is expected.

Biotechnology Pharmaceuticals

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company, announced on September 2, 2026 that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on September 9, 2026. The event will feature management including CEO Ockelbo-Lundgren, CMO Michael A. Panzara, CSO Hella Kohlhof, and President & COO Jason Tay, joined by key opinion leaders Amit Bar-Or of the University of Pennsylvania and Stephen Krieger of the Icahn School of Medicine at Mount Sinai. The R&D day will discuss vidofludimus calcium (IMU-838), an investigational oral therapy combining Nurr1 activation and DHODH inhibition, ahead of the expected top-line data readout from the Phase 3 ENSURE trials in relapsing MS by the end of 2026. The webinar is scheduled from 11:00 am to 12:30 pm ET via Zoom.

60 Immunic announced hosting
stock
Immunic is the host of the R&D day and the developer of vidofludimus calcium. The event is part of its investor relations efforts ahead of Phase 3 data readout.
Importance 100.0 Sentiment 10.0
per
CEO Ockelbo-Lundgren will participate in the R&D day, representing management and discussing the company's strategy.
Importance 60.0 Sentiment 10.0
per
CMO Michael A. Panzara will provide clinical development insights during the R&D day.
Importance 60.0 Sentiment 10.0
per
CSO Hella Kohlhof will discuss the scientific rationale behind vidofludimus calcium.
Importance 60.0 Sentiment 10.0
per
President & COO Jason Tay will participate, representing operational leadership.
Importance 60.0 Sentiment 10.0
per
Key opinion leader Amit Bar-Or will provide expert perspective on MS treatment paradigms.
Importance 40.0 Sentiment 5.0
per
Key opinion leader Stephen Krieger will share insights on MS patient journey and unmet needs.
Importance 40.0 Sentiment 5.0
priv
IR contact for Immunic; no direct impact from the event.
Importance 10.0 Sentiment 0.0
priv
Media contact for Immunic; no direct impact from the event.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.